Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Congo is set to receive 70,000 doses of Merck's Ervebo vaccine as it battles the fastest and largest Ebola outbreak in history. The catch? Ervebo is approved for the Zaire strain, not the Bundibugyo virus driving this outbreak. Early lab and animal data hint at some cross-protection, and 20,000 doses will go toward a Phase III trial to find out for sure.
Congo is receiving 70,000 doses of Merck's Ervebo (rVSVΔG-ZEBOV-GP) vaccine to help contain what the WHO has called the fastest Ebola outbreak in history — but there's a significant asterisk. Ervebo is FDA-approved only against the Zaire ebolavirus strain, while the current outbreak is caused by the Bundibugyo virus, for which no approved vaccine or treatment exists. Early laboratory and animal data suggest the vaccine may offer some protection, but it remains unconfirmed in humans.
Of the 70,000 allocated doses, 20,000 will be used in a Phase III clinical trial to assess the vaccine's effectiveness against Bundibugyo, while the remaining 50,000 will be deployed to protect frontline and healthcare workers. The International Coordinating Group on Vaccine Provision — a partnership of WHO, UNICEF, MSF, and the Red Cross — approved the release following a formal request from Congo's government.
By the Numbers:
Why it matters: With no approved vaccine or treatment for Bundibugyo Ebola, this deployment is both a humanitarian lifeline and a scientific opportunity. The Phase III trial could yield critical new evidence — and potentially reshape outbreak response tools for a virus strain that has long been overlooked.
